Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-04
DOI
10.1007/s00262-020-02619-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.
- (2019) Takashi Kojima et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2
- (2018) Yuko Kitagawa et al. Esophagus
- Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263
- (2018) DAICHI FUJIMOTO et al. ANTICANCER RESEARCH
- Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus
- (2018) Manish A. Shah et al. JAMA Oncology
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- (2017) Toshihiro Kudo et al. LANCET ONCOLOGY
- Elements of cancer immunity and the cancer–immune set point
- (2017) Daniel S. Chen et al. NATURE
- Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
- (2017) Nobuhiro Tsuchiya et al. OncoImmunology
- A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder
- (2016) W Obara et al. ANNALS OF ONCOLOGY
- Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors
- (2016) Mutsunori Murahashi et al. CLINICAL IMMUNOLOGY
- Comprehensive immunohistochemical analysis of tumor microenvironment immune status in esophageal squamous cell carcinoma
- (2016) Ken Hatogai et al. Oncotarget
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers
- (2015) S. Gross et al. Cancer Immunology Research
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Phase II Clinical Trial of Multiple Peptide Vaccination for Advanced Head and Neck Cancer Patients Revealed Induction of Immune Responses and Improved OS
- (2014) Y. Yoshitake et al. CLINICAL CANCER RESEARCH
- Phase I clinical trial of peptide vaccination with URLC10 and VEGFR1 epitope peptides in patients with advanced gastric cancer
- (2014) YOSHIE HIGASHIHARA et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients
- (2014) Hisae Iinuma et al. Journal of Translational Medicine
- Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer
- (2013) Hiroyuki Suzuki et al. Journal of Translational Medicine
- Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens
- (2012) Koji Kono et al. Journal of Translational Medicine
- HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL
- (2008) Michiko Harao et al. INTERNATIONAL JOURNAL OF CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started